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Abstract
Background: Plasmodium vivax is estimated to affect 75 million people annually. It is reportedly
absent, however, from west and central Africa due to the high prevalence of the Duffy negative
phenotype in the indigenous populations. Despite this, non-African travellers consistently return to
their own countries with P. vivax malaria after visiting this region. An attempt was made, therefore,
to detect the presence of P. vivax parasites in blood samples collected from the indigenous
populations of west and central Africa.
Methods: Parasite species typing (for all four human malaria parasites) was carried out by PCR on
2,588 blood samples collected from individuals from nine African malaria-endemic countries.
Results: Most infections (98.5%) were Plasmodium falciparum, Plasmodium malariae was identified
in 8.5% of all infections, and Plasmodium ovale in 3.9%. The prevalence of both parasites varied
greatly by country. Only one case of P. vivax was detected from Sao Tome, an island off the west
coast of Africa, confirming the scarcity of this parasite in Africa.
Conclusion: The prevalence of P. vivax in local populations in sub-Saharan Africa is very low,
despite the frequent identification of this parasite in non-African travellers.
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Background
Plasmodium vivax has the widest geographic range of the
four parasites responsible for malaria in man. Histori-
cally, its range has extended as far north as Finland and
northern China, and as far south as northern Australia
and South Africa [1]. Concerted malaria control initiatives
in countries in temperate zones have today confined P.
vivax mainly to the tropics, where its range overlaps that
of the most important malaria parasite in terms of public
health, Plasmodium falciparum. Thus, the two parasites co-
exist in large parts of the tropical and semi-tropical world,
except, strikingly, in large parts of western and central
Africa, where P. vivax appears to be almost completely
absent [2]. This situation is apparently caused by the high
prevalence of the Duffy negative phenotype in the local
populations, which confers complete protection against
P. vivax malaria [3]. The Duffy antigen/receptor for chem-
okines (DARC) is a transmembrane glycoprotein that is
present on epithelial cells [4], endothelial cells [5], and
erythrocytes. It is utilized by P. vivax parasites as the recep-
tor for attachment to the red cell surface [6]. Duffy nega-
tive individuals are homozygous for a DARC allele,
FY*Bnull, which carries a single nucleotide mutation which
impairs promoter activity by disrupting a binding site for
the h-GATA-1 erythroid transcription factor [7]. This
results in the loss of DARC expression on erythrocytes, but
does not affect expression in epithelial or endothelial
cells. Individuals who are homozygous for this allele thus
express no DARC protein on the red cell surface and are
completely protected from the erythrocytic cycle of P.
vivax. The Duffy negative phenotype occurs in over 95% of
the population of west and central Africa, but is extremely
rare outside Africa and the Arabian peninsula [8].
Present day prevalence of P. vivax in Africa
Although P. vivax is known to be present in parts of north-
ern, eastern and southern Africa, with some areas report-
ing a prevalence of around 20% of all malaria infections
[9], it is extremely rare in west and central Africa. In fact,
there are very few cases of P. vivax in the indigenous pop-
ulation at all, with the exception of the island of Sao
Tome, which is known to harbour all four human malaria
parasites [10]. It is possible that the lack of "local" P. vivax
reported from these areas is due to the fact that its per-
ceived absence precludes its identification. So ingrained
may be the notion of the absence of P. vivax from west and
central Africa that many surveys of parasite species com-
position from these areas do not include assays for the
identification of the parasite [11], and many micro-
scopists automatically designate any parasite associated
with Schüffner's dotted erythrocytes as P. ovale [12]. There
are, however, sporadic reports of its presence. One report
from Equatorial Guinea describes the discovery of four
cases of P. vivax in children of mixed race parentage [13],
and another describes a mild infection of P. vivax in a
Duffy negative woman from the Democratic Republic of
Congo [14]. These rare accounts are supported by more
extensive reports detailing P. vivax infections in non-Afri-
can travellers returning from these areas. For example, an
analysis of 618 imported P. vivax cases diagnosed in Euro-
pean clinics between 1999 and 2003, found that 17% of
travellers had contracted the parasite in west and central
Africa [15]. Furthermore, between 1995 and 1998 there
were 73 reports of P. vivax imported into France from this
region [16]. Imported malaria surveys from the USA
report a similar pattern, with data from 2004 revealing
that 65% of P. vivax imported into the USA from Africa in
that year (n = 67) originated in countries in west and cen-
tral regions [17]. As some of these reports [15,17] rely on
microscopy for identification of parasite species, it may be
argued that confusion between P. ovale and P. vivax may
lead to a degree of misdiagnosis. However, there are an
increasing number of reports that identify parasite species
with molecular techniques [16,18], which are much less
prone to misidentification of species. Given these data, it
seems certain that transmission of P. vivax does occur in
west and central Africa. However, it remains unclear how
transmission is maintained in populations where the
Duffy negative phenotype is almost at fixation.
In 1985, Van Ros described the presence of P. vivax in a
Duffy negative individual [14] from the Democratic
Republic of Congo. Recently, two new reports have also
described this intriguing situation. One, from western
Kenya, describes the presence of P. vivax circumsporozoite
protein in 0.65% of mosquitoes from an area of high
Duffy negativity [19]. More recently, Cavasini et al [20]
reported clear evidence of P. vivax infections in two Duffy
negative individuals in Brazil. It has been proposed that
the parasite may be in the process of evolving mechanisms
which allow the infection of Duffy negative individuals
[21]. Such findings highlight the need for a clear investi-
gation of the prevalence and population dynamics of P.
vivax in west and central Africa, using accurate molecular
species typing methods.
In order to assess the current prevalence of P. vivax in west
and central Africa, PCR species typing of 2,588 samples
from nine different countries throughout the continent
was carried out.
Methods
Blood sample collection and parasite DNA extraction
A total of 2,588 blood samples collated from various sur-
veys undertaken in nine African countries (Figure 1)
between 1998 and 2006 were analysed by PCR for the
presence of each of the four human malaria parasites, P.
falciparum, P. vivax, P. malariae and P. ovale. The original
sample collections were predominantly carried out as part
of unrelated investigations and the methodology of indi-Malaria Journal 2008, 7:174 http://www.malariajournal.com/content/7/1/174
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vidual collection varies. Table 1 outlines the details of
these collections. In all cases, ethical clearance for sam-
pling was obtained from the relevant ethical committees
(for samples collected specifically for this study, details
are given in the following paragraphs).
Samples from Burkina Faso
In 2002, samples were collected from asymptomatic chil-
dren under 10 years old by Active Case Detection (ACD)
in two villages (Bassy and Zanga) 60 Km east of Ouaga-
dougou, the capital of Burkina Faso at the end of the trans-
mission season [22]. DNA was extracted by the use of
TRIZOL® reagent [22]. 108 P. falciparum positive samples
(by PCR), were used in this study.
Figure 1Malaria Journal 2008, 7:174 http://www.malariajournal.com/content/7/1/174
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Samples from Angola, Mozambique, Rwanda, and the 
Democratic Republic of Sao Tome & Principe (DRSTP)
Blood samples were collected by Passive Case Detection
(PCD) at clinics in the following countries: DRSTP, Febru-
ary 2004, at the Centro Policlínico de Saúde de Água
Grande, São Tomé (all ages)[23]; Angola, 2003–2004 at
the Hospital Pediatrico de Luanda (1–5 year olds)[24];
Mozambique from July to October 2004 at the Hospital
Central de Maputo (1–5 year olds)[25]; Rwanda, Novem-
ber to December 2003, at the Rukara Health Centre (1–60
years old)[26]. Only samples identified by thick and thin
smear microscopy as P. falciparum single species infections
were available for analysis. Blood samples were spotted
onto Whatman® n°4 (n°3 in the case of Rwanda) filter
paper and parasite genomic DNA was obtained by boiling
in Chelex-100 [27] and subsequent ethanol precipitation.
Samples from Gabon
206 samples were collected specifically for this study.
Samples were collected in and around Lambarene, Depar-
tement du Moyen Ogooué at five different locations
(Hôpital Albert Schweitzer, Hôpital General de Lam-
baréné, Dispensaire d'Isaac, Adouma and PK48, a village
48 kilometres from Lambaréné). 100–200 μl of venous
blood was applied to Whatman® FTA® Classic Filter paper
cards (Whatman®, USA) and left to air dry. Whatman®
FTA® filter cards deactivate viral DNA/RNA and preserve
human and parasite DNA for downstream analyses. DNA
extractions were carried out according to the manufac-
turer's instructions. Briefly, a disc of 1.2 mm in diameter
was punched from the centre of each dried blood spotted
card and washed three times with Whatman® FTA® Purifi-
cation Reagent, and twice with TE buffer. This treated disc
was then used directly in subsequent PCR analyses. Ethi-
cal clearance for sampling in Gabon was obtained from
the ethical committee of the International Foundation of
the Albert-Schweitzer Hospital and Edinburgh University.
Prior to sampling each patient was informed about the
study, consent was obtained (in the case of children par-
ents/guardians gave informed consent) and medical fol-
low-up was provided if needed.
Samples from the Republic of Congo
359 samples were collected by passive case detection from
two health centres (Madibou and Tenrikyo) within Braz-
zaville, the capital of the Republic of Congo, in 2005. No
age restrictions were applied to sampled individuals.
These samples were collected on Whatman® FTA® filter
paper, and processed as previously described. A further
492 samples were collected in 2006 by PCD from three
separate locations within the Republic of Congo, 150
from Pointe-Noire, on the west coast of the country, a fur-
ther 201 from the Tenrikyo health centre in Brazzaville,
and 141 from Gamboma, a town in the east. These sam-
ples were collected on Whatman® 31ETCHR filter paper,
and DNA extraction was performed using the EZ1 BioRo-
bot™ (QIAGEN, Hilden, Germany) according to the man-
ufacturer's instructions. Ethical approval for this
collection was obtained from the ethical committee at
Osaka University, and sampling was authorized by the
administrative authority of the Ministry for Research and
Ministry for Health in the Republic of Congo. Informed
consent was obtained from individual patients, and anti-
malarial treatment was provided when appropriate.
Samples from Kenya
722 samples were collected in 1998 by active case detec-
tion in the Kisii district of Kenya. All age groups were sam-
pled. Blood was collected by finger-prick on Whatman®
31ETCHR filter paper, and DNA extracted by boiling in
Chelex-100 [27] and subsequent ethanol precipitation.
Ethical clearance for this collection was obtained from the
Ministries of Health and Education in Kenya.
Table 1: Details of sample collections.
Collection area Number Sampling year Sampling method (ACD/PCD)* Age Reference
Burkina Faso1 108 2002 ACD < 10 22
Republic of Congo 851 2005–2006 PCD (clinic) all ages This study
Gabon 206 2005 PCD (clinic) all ages This study
Ghana1 352 2004 ACD < 15 This study
Kenya 722 1998 ACD All ages This study
Sao Tome1,2 70 2004 PCD (clinic) All ages 23
Angola1,2 90 2003–2004 PCD (clinic) 1–5 24
Mozambique1,2 90 2004 PCD (clinic) 1–5 25
Rwanda1,2 99 2003 PCD (clinic) All ages 26
Total 2588
1 Only P. falciparum positive samples were available for analysis
2 Only P. falciparum single species infections (diagnosed by microscopy) were analysed
*ACD; active case detection, PCD; passive case detectionMalaria Journal 2008, 7:174 http://www.malariajournal.com/content/7/1/174
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Samples from Ghana
352 samples were collected by ACD from 0–15 year old
children in four villages near Winneba, a western coastal
region of the country. Finger-prick blood was collected on
Whatman® 31ETCHR filter paper, and DNA extraction was
performed using the EZ1 BioRobot™. This study was
approved by the Ministry of Health/Ghana Health Service.
Species typing PCR
DNA extracted from all samples was subjected to Plasmo-
dium species typing PCR based on the nested PCR tech-
nique developed by Snounou et al [28] with some
modifications. Oligonucleotide primers were identical to
those previously described [28] but the PCR conditions
were modified as follows: For the first round of PCR, 1 μl
of extracted DNA was added to 14.85 μl of dH20, 1.75 μl
of each primer (rPLU5 and rPLU6 at 5 uM), 2.5 μl of
AmpliTaq Gold® 10× PCR Buffer II, 2 μl of 25 mM MgCl2
solution, 1 μl of dNTP mixture (2.5 mM each) and 0.15 μl
of AmpliTaq Gold® in a 25 μl reaction. The following
cycling conditions were applied using a GeneAmp® PCR
9700 thermocycler (Applied Biosystems, USA): 95°C for
10 min, 30 cycles of 57°C for 1 min, 72°C for 1 min,
94°C for 1 min and a final extension step of 72°C for 4
min. 1 μl of the resulting PCR product was used for the
second round of PCR, with an identical reaction mix to
that described for the first round (using pairs of species
specific primers FAL-1 and FAL-2, VIV-1 and VIV-2, MAL-
1 and MAL-2, and OVA-1 and OVA-2), and with the fol-
lowing cycle conditions: 95°C for 10 min, 32 cycles of
94°C for 1 min, 65°C for 1 min, and a final extension step
of 65°C for 5 min. The resulting PCR products were visu-
alized on 2% agarose gels, with the presence or absence of
a band with each species primer pair indicative of the
presence or absence of that species in the initial sample.
Sensitivity of species diagnosis PCR
Prior to commencement of PCR analysis of field samples,
a pilot experiment was carried out to assess the sensitivity
of the PCR conditions detailed above. This protocol con-
sistently detected the presence of P. vivax in a dilution of
genomic DNA that theoretically contained one copy of
the parasite genome per μl (data not shown). Due to var-
iation in DNA extraction technique between sample col-
lections, a consistent volume of blood corresponding to
the 1 μl of extracted genomic DNA used in the PCR cannot
be given. However, it is estimated that no less than 0.5 μl
of initial blood sample was used in each reaction. There-
fore, the PCR detection method used in this investigation
should detect P. vivax parasites in infections of as low as
two parasites per μl of blood. Furthermore, microscopic
evaluation of parasite presence was available for all sam-
ples, and these correlated well with PCR results. Although
the very rare occurrence of a microscopically positive sam-
ple being found to be PCR negative did occur, the vast
majority of discrepancies between microscopy and PCR
diagnosis involved species misdiagnosis by microscopy,
and the detection of parasite infections by PCR in micro-
scopically negative samples, as is expected due to the
greater sensitivity of the PCR technique.
Duffy status profiling
An FY* allele-specific PCR [29] was used to determine the
Duffy status of the individual from Sao Tome infected
with P. vivax. Product amplification took place in a 50 μl
volume reaction containing 5 μl of 10× PCR buffer, 4 μl of
25 mM MgCl2, 0.1 mM of each dNTP, 2 μl of the two 5
μM allele specific primers, 1 μl of the 5 μM control prim-
ers and 6 units of AmpliTaq Gold®  DNA polymerase
(Applied Biosystems, USA). Amplification conditions
were as follows; denaturation and activation of the Ampl-
iTaqGold DNA polymerase at 96°C for 8 min, then 10
cycles of 94° for 20 s and 69°C for 1 min, leading to 25
cycles of 94°C for 20 s, 64°C for 30 s and 72°C for 1 min,
followed by 5 cycles of 94°C for 20 s, 62°C for 30 s and
72°C for 1 min. Amplification of a 411 bp fragment of the
ABO gene acted as the internal control for each reaction.
Results and discussion
Prevalence of P. vivax in sub-Saharan Africa
1,711 samples were positive for P. falciparum (1,526 single
species infections, 51 with P. ovale, 129 with P. malariae,
one with P. vivax and four with both P. malariae and P.
ovale), 67 for P. ovale (12 single infections, 51 mixed with
P. falciparum, and four triple infections with P. falciparum
and P. malariae) 147 for P. malariae (14 single infections,
129 mixed with P. falciparum, and four triple infections
with P. ovale and P. falciparum) and one for P. vivax (mixed
infection with P. falciparum) (Table 2). The only P. vivax
infected sample came from a Duffy positive individual
from Sao Tome, an island off the west coast of Africa. No
P. vivax from any other location within the continent was
detected, confirming the scarcity of this parasite in Africa.
When excluding samples from Rwanda, Mozambique,
Angola and Sao Tome (self-selected as patients identified
by microscopy with a mixed infection were excluded), P.
malariae infections represented 8.5% of all malaria infec-
tions, and P. ovale 3.9%. The prevalence of both parasites
varies greatly by country.
Scarcity of P. vivax
The prevalence of P. vivax in Africa is very low; no evi-
dence for its presence in over 2,500 samples from nine
African countries was found, with the exception of the
island of Sao Tome, from which the parasite had previ-
ously been reported [10]. These results, combined with
the sporadic reports of the transmission of P. vivax in
indigenous populations [10,13,19] and the continued
identification of imported cases originating in west and
central Africa [15,17] indicate that a very low prevalenceMalaria Journal 2008, 7:174 http://www.malariajournal.com/content/7/1/174
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of P. vivax is sufficient to maintain transmission. It is con-
ceivable that in areas with very high entomological inocu-
lation rates (EIR), such as in many areas of west and
central Africa [30], even very low numbers of Duffy posi-
tive individuals may allow the continued transmission of
P. vivax.
That low numbers of Duffy positive individuals in west
and central Africa are sufficient to maintain transmission
on P. vivax, is not surprising considering the very high
basic reproduction number of malaria in this region. The
basic reproductive number of a pathogen, R0, is defined as
the number of new infections arising from an infected
individual introduced into a naïve population. When R0 >
1, transmission is maintained in a population, but when
R0 < 1, transmission is interrupted and the pathogen can-
not persist. A recent report showed that R0 for P. falciparum
malaria transmission in Africa ranges from below one to
nearly 11,000 with a median value of 86, depending on
geographical location [30]. Given that both P. falciparum
and P. vivax are vectored by the same mosquito species,
the only factor that that differentiates R0 for both species
in a given population is the human host's susceptibility to
infection. In order for transmission to be blocked, the pro-
portion of completely immune individuals (p) required in
a population is given by the formula p > 1 - 1/R0. Thus, in
areas where Duffy negativity is present in a population at
a prevalence of up to 99%, as it is in many parts of west
and Central Africa [8], then P. vivax transmission can be
expected to occur when R0 (for P. falciparum) > 100, an
entirely realistic value for many areas. It is entirely con-
ceivable therefore, that P. vivax transmission occurs in
populations in which there are a very high proportion
Duffy negative individuals, given the very high P. falci-
parum R0 values associated with west and central Africa.
A number of researchers have recently suggested that P.
vivax may be in the process of evolving mechanisms [21]
that enable it to infect Duffy positive individuals. Given
the extremely high EIRs and transmission dynamics of
malaria parasites in sub-Saharan Africa, this scenario
would appear highly unlikely given the extremely low
incidences of the parasite reported here. Any P. vivax par-
asite that acquired the ability to infect Duffy negative indi-
viduals may be expected to rapidly spread throughout
sub-Saharan Africa, and would be readily detectable in the
population.
Discrepancy between P. vivax rates in travellers and 
localpopulations
Surveillance of malaria cases imported into the USA
between 2001 and 2005 [31-35], reveals that 32 cases of
P. vivax originated in four west and central African coun-
tries for which we also have species prevalence data from
the local populations. In the same time period, there were
545 cases of imported P. falciparum from the same coun-
tries. This gives a ratio of 100:6 P. falciparum to P. vivax
infections in these areas, a surprisingly high rate, espe-
cially considering that P. malariae and P. ovale are repre-
sented at ratios of 100:6 and 100:5 respectively
(comparable with those of the local populations, see
Table 3). How does one account, then, for the discrepancy
between the imported P. vivax data, and the extremely low
prevalence in the native population reported here?
It is possible that the geographical distribution of P. vivax
within Africa is patchy, with sporadic areas of transmis-
sion scattered throughout the continent, possibly associ-
ated with human populations in which the Duffy negative
phenotype is present at a lower frequency than elsewhere
(such as on the island of Sao Tome). Travellers may pref-
erentially visit areas of west and central Africa where there
is a relatively high frequency of Duffy positive individuals
Table 2: Species composition of isolates analysed by PCR (%)
Collection area Number P. falciparum P. ovale P. malariae P. vivax
Burkina Faso1 108 108 (100) 6 (5.5) 8 (7.4) 0
Congo 851 341 (40.1) 11 (1.3) 8 (0.9) 0
Gabon 206 102 (49.5) 4 (1.9) 1 (0.5) 0
Ghana1 352 352 (100) 8 (2.3) 45 (12.8) 0
Kenya 722 459 (63.6) 35 (4.8) 84 (11.6) 0
Angola1,2 90 90 (100) 0 0 0
Mozambique1,2 90 90 (100) 0 0 0
Rwanda1,2 99 99 (100) 2 (2) 1 (1) 0
Sao Tome1,2 70 70 (100) 1 (1.4) 0 1 (1.4)
Total 2588 1711 67 147 1
1 Only P. falciparum positive samples were available for analysis
2 Only P. falciparum single species infections (diagnosed by microscopy) were analysedMalaria Journal 2008, 7:174 http://www.malariajournal.com/content/7/1/174
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in the local population (e.g. migrant workers and non-
African expatriates) and where P. vivax is more likely to be
transmitted.
Another factor that may contribute to this discrepancy is
the higher transmissibility of P. vivax relative to other
malaria parasites, and in particular relative to P. falci-
parum, under adverse conditions [9]. This has the conse-
quence that there should be higher proportion of P. vivax
relative to P. falciparum in the vector mosquitoes than
there is in the corresponding human population. Conse-
quently travellers, who are a probe of the infection rates in
the local mosquitoes, can be expected to, and indeed do
have (Carter and Mendis, unpublished analysis), higher
proportions of P. vivax than are found in the endemic
human populations amongst whom the travellers have
briefly resided. This may explain the recent findings of
Ryan et al [19], who report the presence of P. vivax in
0.65% of mosquitoes from an area of western Kenya with
a high proportion of Duffy negativity in the local popula-
tion. However, even an extremely small percentage of
Duffy positive individuals in this population may be
expected to support such a rate in mosquitoes.
The use of prophylactic anti-malaria drugs among travel-
lers may also contribute to this phenomenon. Mefloquine
is the recommended prophylactic drug for travellers to
west and central Africa from the USA [31], and whilst
effective against the blood stages of all malaria parasites,
it does not affect the dormant hypnozoite stages of P.
vivax, and will therefore not protect against relapses after
cessation of drug use. This is also true of P. ovale, which is
also capable of producing hypnozoites, and may explain
the slightly higher rate of this parasite in returning travel-
lers compared to the local populations (Table 3).
It is also probable that a small proportion of imported
cases may be P. ovale infections rather than P. vivax, as is
often difficult to distinguish the two species by micros-
copy [15]. As previously mentioned, there are an increas-
ing number of reports detailing imported African P. vivax
diagnosed by accurate molecular typing techniques
[16,18].
In conclusion, the present study indicates that the preva-
lence of P. vivax in local populations in sub-Saharan Africa
is very low, despite the frequent identification of this par-
asite in travellers. P. vivax malaria, therefore, does not con-
stitute a health risk to the indigenous populations of west
and central Africa, though Duffy positive individuals,
including non-African travellers to the area, may be at risk.
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